Multiple Myeloma Clinical Trials
Back to Oncology/Cancer Clinical Trials Main Page
CPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
|---|---|---|---|
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Myeloma Specimen Repository Protocol, Ancillary. SWOG S0309 Visit the Myeloma Specimen Repository study on ClinicalTrials.gov. | Subjects with multiple Myeloma | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Phase II Trial Evaluating Modified High Dose Melphalan (100mg/M2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) Stage II-III MM Diagnosed Within 1yr Of Registration, Protein Criteria Present And/Or Histologically Confirmed Primary Systemic Amyloidosis. SWOG S0115 Visit the SWOG S0115 study on ClinicalTrials.gov. | High risk subjects with multiple Myeloma and/ or light chain Amyloidosis stage II-III diagnosed within 1 yr or registration, protein criteria present and/or histologically confirmed primary Systematic Amyloidosis | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Randomized Phase III Trial of CC_5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) versus Bortezomib, Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously untreated Multiple Myeloma without an Intent for Imeediate Autologous Stem Cell Transplant. SWOG S0777 Visit the SWOG S0777 study on ClinicalTrials.gov. | Subjects with previously untreated Multiple Myeloma without an Intent for Imeediate Autologous Stem Cell Transplant | Closed to Enrollment |
updated: 01/27/10
Back to top